Consistent with the defect in HR, EZH2 inhibition selectively sensitized ovarian cancer cell lines with sufficiently high MAD2L2 levels to PARP inhibitors in both orthotopic and patient-derived xenografts. The gene discussed is EZH2; the disease is ovarian carcinoma.